Last update April 15, 2024

Ethyl methyl 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)pyridine-3,5-dicarboxylate

Compatible

Safe substance and/or breastfeeding is the best option.

It is a dihydropyridine-type calcium channel blocker with actions similar to those of nifedipine. It is used in the treatment of hypertension. Oral administration once or twice a day.

It is excreted into breast milk in clinically non-significant amount (White 1989), possibly due to its high percentage of binding to plasmatic proteins and very wide volume of distribution.

Evidence on other antihypertensive drugs of the same family with similar structure, pharmacokinetics and action profile (nifedipine, nimodipine, nicardipine) has shown that they are excreted into milk in non-significant amount.

Until more extensive published data about this drug regarding breastfeeding are available a safer alternative drug should be used, especially during the neonatal period and/or in case of premature infants.

Alternatives

  • Amlodipine (Safe substance and/or breastfeeding is the best option.)
  • Nifedipine (Safe substance and/or breastfeeding is the best option.)

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.
DONATE NOW

Other names

Ethyl methyl 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)pyridine-3,5-dicarboxylate is Nitrendipine in Chemical name.

Is written in other languages:

Groups

Ethyl methyl 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)pyridine-3,5-dicarboxylate belongs to these groups or families:

Tradenames

Main tradenames from several countries containing Ethyl methyl 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)pyridine-3,5-dicarboxylate in its composition:

List of 18 tradenames

Pharmacokinetics

Variable Value Unit
Oral Bioavail. 10 - 30 %
Molecular weight 360 daltons
Protein Binding 99 %
VD 5 - 9 l/Kg
pKa 16.97 -
Tmax 1 - 3 hours
T½ 10 - 22 hours
M/P ratio 0.2 - 0.5 -
Theoretical Dose 0.001 mg/Kg/d
Relative Dose 0.1 %

References

  1. AEMPS. Nitrendipino. Ficha técnica. 2010 Full text (in our servers)
  2. White WB, Yeh SC, Krol GJ. Nitrendipine in human plasma and breast milk. Eur J Clin Pharmacol. 1989 Abstract
  3. Eichelbaum M, Mikus G, Mast V, Fischer C, Kuhlmann U, Machleidt C. Pharmacokinetics and pharmacodynamics of nitrendipine in healthy subjects and patients with kidney and liver disease. J Cardiovasc Pharmacol. 1988 Abstract

Total visits

504

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by El Parto Es Nuestro of Spain

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM